PDF(Pubmed)
Abstract：
Vaccination against COVID-19 is highly effective in preventing severe disease and hospitalization, but primary COVID mRNA vaccination schedules often differed from those recommended by the manufacturers due to supply chain issues. We investigated the impact of delaying the second dose on antibody responses to COVID mRNA-vaccines in a prospective cohort of health-care workers in Quebec.
We recruited participants from the McGill University Health Centre who provided serum or participant-collected dried blood samples (DBS) at 28-days, 3 months, and 6 months post-second dose and at 28-days after a third dose. IgG antibodies to SARS-CoV2 spike (S), the receptor-binding domain (RBD), nucleocapsid (N) and neutralizing antibodies to the ancestral strain were assessed by enzyme-linked immunosorbent assay (ELISA). We examined associations between long (≤89 days) versus short (<89 days) between-dose intervals and antibody response through multivariable mixed-effects models adjusted for age, sex, prior covid infection status, time since vaccine dose, and assay batch.
The cohort included 328 participants who received up to three vaccine doses (>80% Pfizer-BioNTech). Weighted averages of the serum (n=744) and DBS (n=216) cohort results from the multivariable models showed that IgG anti-S was 31% higher (95% CI: 12% to 53%) and IgG anti-RBD was 37% higher (95% CI: 14% to 65%) in the long vs. short interval participants, across all time points.
Our study indicates that extending the covid primary series between-dose interval beyond 89 days (approximately 3 months) provides stronger antibody responses than intervals less than 89 days. Our demonstration of a more robust antibody response with a longer between dose interval is reassuring as logistical and supply challenges are navigated in low-resource settings.
We recruited participants from the McGill University Health Centre who provided serum or participant-collected dried blood samples (DBS) at 28-days, 3 months, and 6 months post-second dose and at 28-days after a third dose. IgG antibodies to SARS-CoV2 spike (S), the receptor-binding domain (RBD), nucleocapsid (N) and neutralizing antibodies to the ancestral strain were assessed by enzyme-linked immunosorbent assay (ELISA). We examined associations between long (≤89 days) versus short (<89 days) between-dose intervals and antibody response through multivariable mixed-effects models adjusted for age, sex, prior covid infection status, time since vaccine dose, and assay batch.
The cohort included 328 participants who received up to three vaccine doses (>80% Pfizer-BioNTech). Weighted averages of the serum (n=744) and DBS (n=216) cohort results from the multivariable models showed that IgG anti-S was 31% higher (95% CI: 12% to 53%) and IgG anti-RBD was 37% higher (95% CI: 14% to 65%) in the long vs. short interval participants, across all time points.
Our study indicates that extending the covid primary series between-dose interval beyond 89 days (approximately 3 months) provides stronger antibody responses than intervals less than 89 days. Our demonstration of a more robust antibody response with a longer between dose interval is reassuring as logistical and supply challenges are navigated in low-resource settings.
摘要：
■接种COVID-19疫苗在预防严重疾病和住院方面非常有效，但是由于供应链问题，主要的COVIDmRNA疫苗接种时间表通常与制造商建议的时间表有所不同。我们在魁北克省卫生保健工作者的前瞻性队列中调查了延迟第二剂对COVIDmRNA疫苗抗体反应的影响。
■我们招募了来自麦吉尔大学健康中心的参与者，他们在28天提供血清或参与者收集的干血样本（DBS），3个月,第二次给药后6个月和第三次给药后28天。抗SARS-CoV2尖峰（S）的IgG抗体，受体结合域（RBD），通过酶联免疫吸附测定（ELISA）评估核衣壳（N）和祖先菌株的中和抗体。我们通过根据年龄调整的多变量混合效应模型，检查了剂量间隔之间长（≤89天）与短（<89天）与抗体反应之间的关联。性别,先前的covid感染状态，疫苗剂量以来的时间，和测定批次。
■该队列包括328名参与者，他们接受了多达三剂疫苗（>80％Pfizer-BioNTech）。来自多变量模型的血清（n=744）和DBS（n=216）队列结果的加权平均值显示，IgG抗S高出31％（95％CI：12％至53％），IgG抗RBD高出37％（95％CI：14％至65％）。短间隔参与者，在所有时间点。
■我们的研究表明，将covid主要系列的给药间隔延长到89天（约3个月）以上，与少于89天的间隔相比，提供了更强的抗体反应。由于在低资源环境中对后勤和供应挑战进行了导航，因此我们证明了更强大的抗体反应以及更长的剂量间隔令人放心。
■我们招募了来自麦吉尔大学健康中心的参与者，他们在28天提供血清或参与者收集的干血样本（DBS），3个月,第二次给药后6个月和第三次给药后28天。抗SARS-CoV2尖峰（S）的IgG抗体，受体结合域（RBD），通过酶联免疫吸附测定（ELISA）评估核衣壳（N）和祖先菌株的中和抗体。我们通过根据年龄调整的多变量混合效应模型，检查了剂量间隔之间长（≤89天）与短（<89天）与抗体反应之间的关联。性别,先前的covid感染状态，疫苗剂量以来的时间，和测定批次。
■该队列包括328名参与者，他们接受了多达三剂疫苗（>80％Pfizer-BioNTech）。来自多变量模型的血清（n=744）和DBS（n=216）队列结果的加权平均值显示，IgG抗S高出31％（95％CI：12％至53％），IgG抗RBD高出37％（95％CI：14％至65％）。短间隔参与者，在所有时间点。
■我们的研究表明，将covid主要系列的给药间隔延长到89天（约3个月）以上，与少于89天的间隔相比，提供了更强的抗体反应。由于在低资源环境中对后勤和供应挑战进行了导航，因此我们证明了更强大的抗体反应以及更长的剂量间隔令人放心。
